King Luther Capital Management Corp Increases Stock Position in scPharmaceuticals Inc. (NASDAQ:SCPH)

King Luther Capital Management Corp boosted its holdings in scPharmaceuticals Inc. (NASDAQ:SCPH) by 28.4% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,857,910 shares of the company’s stock after buying an additional 632,120 shares during the period. King Luther Capital Management Corp owned approximately 0.06% of scPharmaceuticals worth $10,117,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Suvretta Capital Management LLC purchased a new position in shares of scPharmaceuticals in the third quarter valued at $9,343,000. Rubric Capital Management LP boosted its stake in scPharmaceuticals by 35.5% in the 3rd quarter. Rubric Capital Management LP now owns 4,775,000 shares of the company’s stock worth $21,774,000 after purchasing an additional 1,250,000 shares during the period. Rice Hall James & Associates LLC grew its holdings in scPharmaceuticals by 59.2% during the 4th quarter. Rice Hall James & Associates LLC now owns 989,635 shares of the company’s stock valued at $3,503,000 after buying an additional 367,970 shares in the last quarter. Stonepine Capital Management LLC increased its position in shares of scPharmaceuticals by 84.7% during the third quarter. Stonepine Capital Management LLC now owns 778,874 shares of the company’s stock valued at $3,552,000 after buying an additional 357,171 shares during the period. Finally, Walleye Capital LLC lifted its holdings in shares of scPharmaceuticals by 27.0% in the third quarter. Walleye Capital LLC now owns 475,555 shares of the company’s stock worth $2,169,000 after buying an additional 101,148 shares in the last quarter. Institutional investors own 89.52% of the company’s stock.

scPharmaceuticals Stock Performance

Shares of SCPH opened at $3.08 on Wednesday. The company has a current ratio of 8.08, a quick ratio of 6.89 and a debt-to-equity ratio of 1.66. The stock has a 50-day moving average price of $3.36 and a 200-day moving average price of $3.90. The company has a market cap of $154.12 million, a PE ratio of -1.62 and a beta of 0.40. scPharmaceuticals Inc. has a 12-month low of $2.75 and a 12-month high of $6.20.

Wall Street Analyst Weigh In

SCPH has been the subject of several recent analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $18.00 price objective on shares of scPharmaceuticals in a research note on Monday, March 3rd. Craig Hallum decreased their price target on shares of scPharmaceuticals from $16.00 to $12.00 and set a “buy” rating on the stock in a report on Thursday, November 14th.

About scPharmaceuticals

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.